Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085189 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00085189 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 42 participants.
The verdict
NCT00085189, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells
Interventions
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL gp100 antigen
- BIOLOGICAL multi-epitope melanoma peptide vaccine
- BIOLOGICAL tyrosinase peptide
- BIOLOGICAL recombinant MAGE-3.1 antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-05 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085189
The ClinicalTrials.gov registry entry for NCT00085189 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which incomplete Freund's adjuvant is the first listed.
NCT00085189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085189 about?
NCT00085189 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma". This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells
What is the current status of trial NCT00085189?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2004-05. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00085189?
The interventions under investigation include: incomplete Freund's adjuvant (BIOLOGICAL), gp100 antigen (BIOLOGICAL), multi-epitope melanoma peptide vaccine (BIOLOGICAL), tyrosinase peptide (BIOLOGICAL), recombinant MAGE-3.1 antigen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085189?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.